Molecule News and Research

RSS

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Richmont establishes distribution of PURE's SDC-based IV-7 products in Middle East

PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that its marketing partner, Richmont Sciences (Richmont), has established distribution of PURE's SDC-based IV-7™ products in the Middle East region. Under this arrangement, PURE sells IV-7 products to Richmont for resale into the Middle East, where the IV-7 water treatment and disinfection products have been registered by the United Arab Emirates-Dubai Municipality. Richmont is initially focusing on distribution of IV-7 Water Treatment™.

28 Oct 2010

Immune system may play a role in cancer therapies: Study

The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell.

28 Oct 2010

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

The Methodist Hospital Research Institute® (TMHRI) today opened a 12-story, 440,000 square foot research facility dedicated solely to research and equipped with the world's most advanced technology to help research scientists, physicians and engineers cure diseases that afflict today's patients.

28 Oct 2010

Scientists suggest E-cadherin can function as oncogene in some cancers

Researchers at Mayo Clinic in Florida have found that a molecule long believed to be a beneficial tumor suppressor and thus a potential cancer drug target appears to act as an oncogene in some lethal brain tumors.

28 Oct 2010

BioNanomatrix nanoAnalyzer 1000 System to be introduced at ASHG Annual Meeting

BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, will introduce next month the nanoAnalyzer 1000 System at the American Society of Human Genetics (ASHG) Annual Meeting from November 2-6, 2010 in Washington, D.C.

28 Oct 2010

Scientists develop new imaging technique that can detect breast cancer treatment response

Cancer Research UK scientists have developed a new imaging technique that can show when breast cancer treatment is working, weeks before current methods. The research is published in the British Journal of Cancer today1 (Wednesday).

27 Oct 2010

Evotec, Apeiron Biologics enter collaboration

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

27 Oct 2010

Study suggests need to explore new infertility tests

The method used to assess infertility in at-home tests might not be the best for identifying which women will have trouble getting pregnant, according to new research from the University of North Carolina at Chapel Hill School of Medicine.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010

Tripos releases new version of SYBYL-X for QSAR studies

Tripos, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.2.

27 Oct 2010

Pacific Biosciences prices initial public offering of common stock

Pacific Biosciences of California, Inc. developer of single molecule, real-time (SMRT) technology for biological analysis, announced today the pricing of its initial public offering of 12,500,000 shares of its common stock at $16.00 per share. All shares are being sold by the company.

27 Oct 2010

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

From Vitabiotics Ltd. 26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

Molecule News and Research

Mechanism that controls embryonic development could also prevent cancer

Novel small molecule inhibitors may provide new therapy for colon cancer

New findings on Th17 cells pave way for human cancer treatment protocol

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Richmont establishes distribution of PURE's SDC-based IV-7 products in Middle East

Immune system may play a role in cancer therapies: Study

The Methodist Hospital Research Institute opens 12-story, 440,000 square foot research facility

Scientists suggest E-cadherin can function as oncogene in some cancers

BioNanomatrix nanoAnalyzer 1000 System to be introduced at ASHG Annual Meeting

Scientists develop new imaging technique that can detect breast cancer treatment response

Evotec, Apeiron Biologics enter collaboration

Study suggests need to explore new infertility tests

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

Tripos releases new version of SYBYL-X for QSAR studies

Pacific Biosciences prices initial public offering of common stock

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

IDC grants MedImmune global rights to GLA adjuvant

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News